Differential gene expression induced by anti-cancer agent plumbagin is mediated by androgen receptor in prostate cancer cells

Sci Rep. 2018 Feb 9;8(1):2694. doi: 10.1038/s41598-018-20451-9.

Abstract

Treatment of mice harboring PTEN-P2 tumors in the prostate or on prostate tissue in vivo with 5-hydroxy-2-methyl-1,4-naphthoquinone, also known as plumbagin, results in tumor regression in castrated mice, but not in intact mice. This suggested that dihydrotestosterone (DHT) production in the testes may prevent cell death due to plumbagin treatment, but the underlying mechanism is not understood. We performed RNA-seq analysis on cells treated with combinations of plumbagin and DHT, and analyzed differential gene expression, to gain insight into the interactions between androgen and plumbgin. DHT and plumbagin synergize to alter the expression of many genes that are not differentially regulated by either single agent when used alone. These experiments revealed that, for many genes, increases in mRNAs caused by DHT are sharply down-regulated by plumbagin, and that many transcripts change in response to plumbagin in a DHT-dependent manner. This suggests that androgen receptor mediates some of the effects of plumbagin on gene expression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgens / pharmacology
  • Animals
  • Cell Line, Tumor
  • Dihydrotestosterone / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Male
  • Mice
  • Naphthoquinones / metabolism
  • Naphthoquinones / pharmacology*
  • Prostate / pathology
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*
  • Testis / metabolism
  • Transcriptome / drug effects
  • Transcriptome / genetics

Substances

  • Androgens
  • Naphthoquinones
  • Receptors, Androgen
  • Dihydrotestosterone
  • plumbagin